Filing Details
- Accession Number:
- 0000950170-24-084346
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-07-17 17:35:34
- Reporting Period:
- 2024-07-15
- Accepted Time:
- 2024-07-17 17:35:34
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1658247 | Crinetics Pharmaceuticals Inc. | CRNX | Pharmaceutical Preparations (2834) | 263744114 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1881007 | E. Jeff Knight | C/O Crinetics Pharmaceuticals, Inc. 6055 Lusk Boulevard San Diego CA 92121 | Chief Operating Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2024-07-15 | 17,499 | $23.98 | 70,079 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-07-15 | 2,887 | $20.02 | 72,966 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2024-07-15 | 5,687 | $19.64 | 78,653 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2024-07-15 | 27,000 | $55.00 | 51,653 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock option (Right to Buy) | Disposition | 2024-07-15 | 17,499 | $0.00 | 17,499 | $23.98 |
| Common Stock | Stock option (Right to Buy) | Disposition | 2024-07-15 | 2,887 | $0.00 | 2,887 | $20.02 |
| Common Stock | Stock option (Right to Buy) | Disposition | 2024-07-15 | 5,687 | $0.00 | 5,687 | $19.64 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 112,501 | 2031-09-01 | No | 4 | M | Direct | |
| 20,213 | 2032-02-29 | No | 4 | M | Direct | |
| 85,313 | 2033-03-01 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- The option is exercisable as follows: 25% of the shares subject to the option vest on August 30, 2022, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- 1/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- 1/48th of the shares subject to the option vested on April 1, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Billionaire Hedge Funds
